Navigation path

Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Purevax RCPCh FeLV   
Auth. number : EU/2/04/047
Active substance : Not available
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI06 - Immunologicals for felidae
Pharmacological subgroup: QI06A - Cat
Chemical subgroup: QI06AX - Other immunologicals
Chemical substance: QI06AX - Other immunologicals
(See WHO ATCvet Index)
Indication: Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs,
- against Chlamydophila felis infection to reduce clinical signs,
- against feline panleucopenia to prevent mortality and clinical signs,
- against leukaemia to prevent persistent viraemia and clinical signs of the related disease.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.
The duration of immunity after the last re-vaccination is 3 years for the rhinotracheitis, calicivirosis and panleucopenia components, and 1 year for the Chlamydophila felis and feline leukaemia components.
Marketing Authorisation Holder: Merial
29 avenue Tony Garnier, 69007 Lyon, France
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/02/2005 Centralised - Authorisation EMEA/V/C/85 (2005)470 of 23/02/2005
24/07/2005 Centralised - Variation (no change in Commission Decision) EMEA/V/C/85/I/1
25/01/2008 Centralised - Variation EMEA/V/C/85/II/2, 3, 4 (2007)338 of 22/01/2008
23/09/2008 Centralised - Variation (no change in Commission Decision) EMEA/V/C/85/II/5
17/02/2009 Centralised - Variation EMEA/V/C/85/II/6 (2009)1100 of 13/02/2009
19/01/2010 Centralised - Renewal EMEA/V/C/85/R/7 (2010)122 of 15/01/2010
15/01/2015 Centralised - Variation EMEA/V/C/85/WS/606
Updated with Decision(2016)412 of 22/01/2016
26/01/2016 Centralised - Yearly update (2016)412 of 22/01/2016